Potent Immunogenicity and Neutralization of Recombinant Adeno-associated Virus Expressing the Glycoprotein of Severe Fever with Thrombocytopenia Virus

Overview

Journal J Vet Med Sci

Specialty Veterinary Medicine

Date 2023 Dec 24

PMID 38143087

Authors

Toshiaki Shimoyama

Mami Oba

Hitoshi Takemae

Tsutomu Omatsu

Hideki Tani

Tetsuya Mizutani

Affiliations

Soon will be listed here.

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an infectious disease caused by a tick-borne virus called severe fever with thrombocytopenia syndrome virus (SFTSV). In recent years, human infections through contact with ticks and through contact with the bodily fluids of infected dogs and cats have been reported; however, no vaccine is currently available. SFTSV has two glycoproteins (Gn and Gc) on its envelope, which are vaccine-target antigens involved in immunogenicity. In the present study, we constructed novel SFTS vaccine candidates using an adeno-associated virus (AAV) vector to transport the SFTSV glycoprotein genome. AAV vectors are widely used in gene therapy and their safety has been confirmed in clinical trials. Recently, AAV vectors have been used to develop influenza and SARS-CoV-2 vaccines. Two types of vaccines (AAV9-SFTSV Gn and AAV9-SFTSV Gc) carrying SFTSV Gn and Gc genes were produced. The expression of Gn and Gc proteins in HEK293T cells was confirmed by infection with vaccines. These vaccines were inoculated into mice, and the collected sera produced anti-SFTS antibodies. Furthermore, sera from AAV9-SFTSV Gn infected mice showed a potent neutralizing ability, similar to previously reported SFTS vaccine candidates that protected animals from SFTSV infection. These findings suggest that this vaccine is a promising candidate for a new SFTS vaccine.

References

Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T . The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 2013; 209(6):816-27. PMC: 7107388. DOI: 10.1093/infdis/jit603. View

Tani H, Kawachi K, Kimura M, Taniguchi S, Shimojima M, Fukushi S . Identification of the amino acid residue important for fusion of severe fever with thrombocytopenia syndrome virus glycoprotein. Virology. 2019; 535:102-110. DOI: 10.1016/j.virol.2019.06.014. View

Yu X, Liang M, Zhang S, Liu Y, Li J, Sun Y . Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011; 364(16):1523-32. PMC: 3113718. DOI: 10.1056/NEJMoa1010095. View

Peng J, Zou W, Wang X, Zhang Z, Huo R, Yang L . Viral-mediated gene therapy in pediatric neurological disorders. World J Pediatr. 2023; 20(6):533-555. DOI: 10.1007/s12519-022-00669-4. View

Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I . Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods. 2012; 23(1):18-28. DOI: 10.1089/hgtb.2011.034. View

Du L, He Y, Wang Y, Zhang H, Ma S, Wong C . Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology. 2006; 353(1):6-16. PMC: 7111904. DOI: 10.1016/j.virol.2006.03.049. View

Ploquin A, Szecsi J, Mathieu C, Guillaume V, Barateau V, Ong K . Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines. J Infect Dis. 2012; 207(3):469-78. PMC: 7107322. DOI: 10.1093/infdis/jis699. View

Nieto K, Salvetti A . AAV Vectors Vaccines Against Infectious Diseases. Front Immunol. 2014; 5:5. PMC: 3896988. DOI: 10.3389/fimmu.2014.00005. View

Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R . Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine. 2011; 29(8):1690-9. DOI: 10.1016/j.vaccine.2010.12.037. View

10.

Wu Y, Zhu Y, Gao F, Jiao Y, Oladejo B, Chai Y . Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. Proc Natl Acad Sci U S A. 2017; 114(36):E7564-E7573. PMC: 5594662. DOI: 10.1073/pnas.1705176114. View

11.

Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan C . Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006; 108(1):107-15. DOI: 10.1182/blood-2005-12-5115. View

12.

Kang J, Jeon K, Choi H, Kim Y, Kim H, Ro H . Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice. PLoS Negl Trop Dis. 2020; 14(3):e0007813. PMC: 7112229. DOI: 10.1371/journal.pntd.0007813. View

13.

Dong F, Li D, Wen D, Li S, Zhao C, Qi Y . Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. NPJ Vaccines. 2019; 4:5. PMC: 6347601. DOI: 10.1038/s41541-018-0096-y. View

14.

Yoshikawa T, Taniguchi S, Kato H, Iwata-Yoshikawa N, Tani H, Kurosu T . A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome. PLoS Pathog. 2021; 17(2):e1008859. PMC: 7886154. DOI: 10.1371/journal.ppat.1008859. View

15.

Luo L, Zhao L, Wen H, Zhang Z, Liu J, Fang L . Haemaphysalis longicornis Ticks as Reservoir and Vector of Severe Fever with Thrombocytopenia Syndrome Virus in China. Emerg Infect Dis. 2015; 21(10):1770-6. PMC: 4593435. DOI: 10.3201/eid2110.150126. View

16.

Halldorsson S, Behrens A, Harlos K, Huiskonen J, Elliott R, Crispin M . Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion. Proc Natl Acad Sci U S A. 2016; 113(26):7154-9. PMC: 4932967. DOI: 10.1073/pnas.1603827113. View

17.

Blair H . Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy. CNS Drugs. 2022; 36(9):995-1005. DOI: 10.1007/s40263-022-00941-1. View

18.

Zhao J, Yue Y, Patel A, Wasala L, Karp J, Zhang K . High-Resolution Histological Landscape of AAV DNA Distribution in Cellular Compartments and Tissues following Local and Systemic Injection. Mol Ther Methods Clin Dev. 2020; 18:856-868. PMC: 7479330. DOI: 10.1016/j.omtm.2020.08.006. View

19.

Kaplitt M, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor P . Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007; 369(9579):2097-105. DOI: 10.1016/S0140-6736(07)60982-9. View

20.

Hulswit R, Paesen G, Bowden T, Shi X . Recent Advances in Bunyavirus Glycoprotein Research: Precursor Processing, Receptor Binding and Structure. Viruses. 2021; 13(2). PMC: 7926653. DOI: 10.3390/v13020353. View